香港股市 已收市

Rain Oncology Inc. (RAIN)

NasdaqGS - NasdaqGS 即時價格。貨幣為 USD。
加入追蹤清單
8.50-0.13 (-1.51%)
收市價: 04:00PM EDT
8.30 -0.20 (-2.35%)
收市後: 06:47PM EDT
全螢幕
交易股價資料並非來自所有市場
前收市價8.63
開市8.57
買盤8.43 x 1100
賣出價8.87 x 800
今日波幅8.31 - 8.74
52 週波幅2.15 - 14.48
成交量110,291
平均成交量262,559
市值309.028M
Beta 值 (5 年,每月)
市盈率 (最近 12 個月)
每股盈利 (最近 12 個月)-2.94
業績公佈日2023年5月02日 - 2023年5月08日
遠期股息及收益率無 (無)
除息日
1 年預測目標價18.18
  • Insider Monkey

    Rain Therapeutics Inc. (NASDAQ:RAIN) Q4 2022 Earnings Call Transcript

    Rain Therapeutics Inc. (NASDAQ:RAIN) Q4 2022 Earnings Call Transcript March 9, 2023 Operator: Greetings and welcome to the Rain Oncology Fourth Quarter and Full Year 2022 Earnings Call. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Dan Ferry of Live Site Advisors. Thank you. You may […]

  • Benzinga

    Rain Therapeutics Experimental Cancer Therapy Shows Encouraging Tumor Regression Activity

    Rain Therapeutics Inc (NASDAQ: RAIN) announced preliminary data from Phase 2 basket trial evaluating milademetan for MDM2-amplified advanced solid tumors. "Treatment with milademetan led to tumor regression in patients previously treated with a multitude of therapies across a range of cancers. We look forward to expanding this dataset as the trial continues to enroll," said Avanish Vellanki, co-founder & CEO. Seventeen patients have been enrolled, 15 of whom have been dosed with milademetan. Ten

  • Benzinga

    This Cancer Focused Stock Has 60% Potential Upside, Bullish Analyst Says

    HC Wainwright initiated coverage on Rain Therapeutics Inc (NASDAQ: RAIN), with a price target of $10 with a Buy rating. With an upside of almost 60%, the analyst believes Rain's lead asset, milademetan, has the potential to become a tumor-agnostic therapy for MDM2 amplified cancers. Milademetan, in-licensed from Daiichi Sankyo (OTC: DSNKY) in 2020, is an oral MDM2 inhibitor that reactivates the tumor suppressor gene, p53. P53 is a key regulator of various cellular processes, including the cell c